Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.21%
1,096.17
+2.36
+0.21%
—1,093.811,096.521,100.221,093.20——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.10
+1.33
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.37%
1,237.68
-17.13
-1.37%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.68%
1,749.14
-11.97
-0.68%
—1,761.111,764.271,766.881,745.39——
SIXM
Financials
SIXM
Financials
SIXM
-0.10%
641.91
-0.69
-0.10%
—642.58644.87648.48641.88——
SIXR
Staples
SIXR
Staples
SIXR
-0.56%
846.40
-4.73
-0.56%
—851.13855.66858.75845.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.36%
217.19
-0.79
-0.36%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.62%
3,263.96
+52.13
+1.62%
—3,211.833,227.213,267.763,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.60%
943.25
-5.73
-0.60%
—948.98948.58957.83943.00——
SIXV
Health care
SIXV
Health care
SIXV
-0.31%
1,469.99
-4.53
-0.31%
—1,474.521,479.031,481.041,469.17——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.56%
2,405.50
+13.38
+0.56%
—2,392.122,396.952,421.222,382.32——
Q1 2026 earnings • released • EPS beat +5.66% • Revenue beat +55.57%
See results
AGIO:NASDAQ
Agios Pharmaceuticals Inc
$28.19
+0.68%
(+0.19) 1D
May 1, 2:48:34 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGIO...
Open
$28.00
High
$28.30
Low
$27.25
Mkt. cap
1.68B
Avg. vol.
1.13M
Volume
588.45K
52-wk high
$45.99
52-wk low
$22.24
EPS
-$7.25
Beta
0.79
Shares outstanding
59.47M
No. of employees
540
News stories
From sources across the web
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
CEO-
Employees540
Founded2008
Headquarters-
SectorBiotechnology
Websiteagios.com
Last report
Apr 29, 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-1.69/ (-1.79 est.)USD
+5.66%beat
Revenue / Estimate
20.75M/ (13.34M est.)USD
+55.57%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
12.46M
12.88M
19.97M
20.75M
Cost of goods sold
93.64M
88.48M
89.94M
1.32M
Cost of revenue
93.64M
88.48M
89.94M
1.32M
Research and development expenses
-
-
-
81.15M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
45.87M
41.27M
51.61M
48.30M
Operating expense
45.87M
41.27M
51.61M
129.45M
Total operating expenses
139.51M
129.75M
141.54M
130.77M
Operating income
-127.06M
-116.87M
-121.58M
-110.02M
Other non operating income
523.00K
67.00K
113.00K
-
EBT including unusual items
-112.02M
-103.43M
-109.06M
-99.11M
EBT excluding unusual items
-112.02M
-103.43M
-109.06M
-
Income tax expense
-
-
-1.02M
-
Effective tax rate
-
-
0.93%
-
Other operating expenses
-
-
-
-
Net income
-112.02M
-103.43M
-108.04M
-99.11M
Net profit margin
-899.40%
-803.05%
-541.09%
-477.74%
Earnings per share
-1.93
-1.78
-1.85
-1.69
Interest and investment income
14.51M
13.37M
12.41M
10.80M
Interest expense
-
-
-
-
Net interest expenses
14.51M
13.37M
12.41M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-125.80M
-115.50M
-120.31M
-108.73M
Gain or loss from assets sale
5.00K
299.00K
-299.00K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer